Avoiding Overanticoagulation: Pharmacogenomics or Pragmatism?

Thromb Haemost 2001; 85(05): 945-946
DOI: 10.1055/s-0037-1615779

Letters to the Editor

Schattauer GmbH

Trevor Baglin

¹Department of Haematology, Addenbrooke‘s Hospital, Cambridge University Hospitals Trust, Cambridge, UK

References
1 Margaglione M, Colaizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
2 Mannucci P. Genetic control of anticoagulation. Lancet 1999; 353: 688-9.
3 Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrtome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
4 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
5 Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998; 103: 422-4.
6 Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at ALA-10 in the factor IX propeptide?. Br J Haematol 1997; 99: 467-8.